Literature DB >> 22575718

Content development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction.

Lynne I Wagner1, Don Robinson, Matthias Weiss, Michael Katz, Phillip Greipp, Rafael Fonseca, David Cella.   

Abstract

CONTEXT: Multiple myeloma (MM) is a common hematologic malignancy and is associated with symptom burden and impairments in health-related quality of life (HRQL).
OBJECTIVES: To develop a disease-specific, patient-reported outcome (PRO) measure for the assessment of HRQL among patients with MM as part of the Functional Assessment of Cancer Therapy (FACT) measurement system.
METHODS: HRQL concerns and symptoms associated with MM were tabulated based on a literature review, and 52 candidate PRO items were identified. Expert clinicians (n=13) rated 52 items on relevance to HRQL for MM patients (0-3 scale). Experts added 11 items for comprehensive PRO assessment in MM. A list of 63 candidate items was rated (0-3 scale) by 13 MM patients enrolled through the International Myeloma Foundation website. Qualitative data and quantitative item ratings were reviewed to select FACT-MM scale items.
RESULTS: Expert clinicians provided the highest HRQL relevance ratings for bone pain, bodily pain, difficulty walking (2.9), tiring easily (2.6), feeling discouraged (2.5), interference with activities and difficulty with self-care as a result of bone pain (2.5), and fatigue (2.5). Mean age of patients was 57 years; Eastern Cooperative Oncology Group performance status was 0 (38%), 1 (31%), or 2 (31%). Quantitative ratings by patients identified sexual function (1.3), uncertainty about health (1.2), fatigue (1.0), weight gain (1.0), and emotional concerns, such as worry about new symptoms and difficulty planning for the future (1.0) as most relevant to HRQL.
CONCLUSION: The 14-item FACT-MM PRO measure was developed based on expert clinician and patient data, ensuring relevance to HRQL for MM patients.
Copyright © 2012 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22575718      PMCID: PMC3419469          DOI: 10.1016/j.jpainsymman.2011.06.019

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  14 in total

1.  Web surveys: a review of issues and approaches.

Authors:  M Couper
Journal:  Public Opin Q       Date:  2000

2.  Evaluation of qualitative research studies.

Authors:  Cynthia K Russell; David M Gregory
Journal:  Evid Based Nurs       Date:  2003-04

Review 3.  Multiple myeloma: a review of the epidemiologic literature.

Authors:  Dominik D Alexander; Pamela J Mink; Hans-Olov Adami; Philip Cole; Jack S Mandel; Martin M Oken; Dimitrios Trichopoulos
Journal:  Int J Cancer       Date:  2007       Impact factor: 7.396

4.  Pain, mood disturbance, and quality of life in patients with multiple myeloma.

Authors:  A R Poulos; M A Gertz; V S Pankratz; J Post-White
Journal:  Oncol Nurs Forum       Date:  2001-08       Impact factor: 2.172

5.  Metaanalysis of the correlation between radiographic tumor response and patient-reported outcomes.

Authors:  David Victorson; Mehul Soni; David Cella
Journal:  Cancer       Date:  2006-02-01       Impact factor: 6.860

6.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.

Authors:  D F Cella; D S Tulsky; G Gray; B Sarafian; E Linn; A Bonomi; M Silberman; S B Yellen; P Winicour; J Brannon
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

Review 7.  Individualizing treatment of patients with myeloma in the era of novel agents.

Authors:  Jesús San-Miguel; Jean-Luc Harousseau; Douglas Joshua; Kenneth C Anderson
Journal:  J Clin Oncol       Date:  2008-04-21       Impact factor: 44.544

Review 8.  Multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Blood       Date:  2008-03-15       Impact factor: 22.113

9.  Psychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantation.

Authors:  A C Sherman; S Simonton; U Latif; R Spohn; G Tricot
Journal:  Bone Marrow Transplant       Date:  2004-05       Impact factor: 5.483

Review 10.  The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation.

Authors:  Kimberly Webster; David Cella; Kathleen Yost
Journal:  Health Qual Life Outcomes       Date:  2003-12-16       Impact factor: 3.186

View more
  21 in total

Review 1.  Engaging Patients as Partners in Developing Patient-Reported Outcome Measures in Cancer-A Review of the Literature.

Authors:  Natasha Camuso; Prerna Bajaj; Deborah Dudgeon; Gunita Mitera
Journal:  Support Care Cancer       Date:  2016-03-28       Impact factor: 3.603

2.  Validation of the M. D. Anderson Symptom Inventory multiple myeloma module.

Authors:  Desiree Jones; Elisabeth G Vichaya; Xin Shelley Wang; Loretta A Williams; Nina D Shah; Sheeba K Thomas; Valen E Johnson; Richard E Champlin; Charles S Cleeland; Tito R Mendoza
Journal:  J Hematol Oncol       Date:  2013-02-05       Impact factor: 17.388

3.  Improving the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the Myeloma Patient Outcome Scale (MyPOS).

Authors:  Thomas R Osborne; Christina Ramsenthaler; Stephen A Schey; Richard J Siegert; Polly M Edmonds; Irene J Higginson
Journal:  BMC Cancer       Date:  2015-04-14       Impact factor: 4.430

Review 4.  Quality of life and supportive care in multiple myeloma.

Authors:  Melda Cömert; Ajda Ersoy Güneş; Fahri Sahin; Güray Saydam
Journal:  Turk J Haematol       Date:  2013-09-05       Impact factor: 1.831

5.  Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) was established using traditional, generalizability and Rasch psychometric methods.

Authors:  Christina Ramsenthaler; Wei Gao; Richard J Siegert; Steve A Schey; Poly M Edmonds; Irene J Higginson
Journal:  Qual Life Res       Date:  2017-07-27       Impact factor: 4.147

6.  Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma.

Authors:  Deepti Soodgupta; Michelle A Hurchla; Majiong Jiang; Alexander Zheleznyak; Katherine N Weilbaecher; Carolyn J Anderson; Michael H Tomasson; Monica Shokeen
Journal:  PLoS One       Date:  2013-02-08       Impact factor: 3.240

Review 7.  Review of health-related quality of life data in multiple myeloma patients treated with novel agents.

Authors:  P Sonneveld; S G Verelst; P Lewis; V Gray-Schopfer; A Hutchings; A Nixon; M T Petrucci
Journal:  Leukemia       Date:  2013-06-20       Impact factor: 11.528

8.  Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life.

Authors:  Thomas R Osborne; Christina Ramsenthaler; Susanne de Wolf-Linder; Stephen A Schey; Richard J Siegert; Polly M Edmonds; Irene J Higginson
Journal:  BMC Cancer       Date:  2014-07-09       Impact factor: 4.430

9.  The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials.

Authors:  Don Robinson; Dixie-Lee Esseltine; Antoine Regnault; Juliette Meunier; Kevin Liu; Helgi van de Velde
Journal:  Br J Haematol       Date:  2016-06-05       Impact factor: 6.998

10.  Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project.

Authors:  Joan Blade; Miguel Ángel Calleja; Juan José Lahuerta; José Luis Poveda; Héctor David de Paz; Luis Lizán
Journal:  BMJ Open       Date:  2018-02-22       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.